Menu
Not yet recruiting NCT07625930

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

Phase II Interventional Gastroesophageal Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab.
Who it may be relevant to
Registry conditions: Gastroesophageal Adenocarcinoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial: A Phase II Randomized Open-Label Trial of Perioperative Simvastatin Plus Standard-of-Care Systemic Therapy in Gastroesophageal Adenocarcinoma

Overview

Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed. This study will test whether adding a commonly used cholesterol-lowering medication, simvastatin, to standard cancer treatment can improve outcomes. Simvastatin is widely used, safe, and inexpensive. Research suggests that it may also slow cancer growth by blocking pathways that cancer cells rely on for survival. In this trial, patients will receive standard chemotherapy (with or without immunotherapy) before surgery. Half of the patients will also take simvastatin daily for up to two years. Researchers will compare how well tumors respond to treatment and whether patients remain cancer-free longer. If successful, this approach could offer a simple and accessible way to improve survival for patients with these cancers without adding significant side effects or cost.

Interventions

  • Drug FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
    Standard of care neoadjuvant FLOT
  • Drug Simvastatin
    Investigational drug added to standard of care FLOT or FLOT+D
  • Drug Durvalumab
    Standard of care Durvalumab added to FLOT regimen.

Primary outcome measures

  • MPR [Time frame: From enrolment to surgical pathology assessment, 16 weeks]
Secondary outcome measures (2)
  • Statin-enhanced toxicity of standard-of-care regimen, specifically grade 3 or 4 adverse events [Time frame: Start of neoadjuvant therapy to the end of adjuvant therapy (weeks 2-28)]
  • 2-year EFS [Time frame: Elapsed time from date of randomization to date of recurrence or death, within 2 years from resection]

Eligibility criteria

Inclusion criteria

  • Signed, informed consent.
  • Age, 18 years or older.
  • Histological diagnosis of adenocarcinoma or poorly differentiated carcinoma of the esophagus or EGJ.
  • The tumour must be deemed potentially resectable by the surgical team. This assessment is based on complete staging imaging studies (detailed below) - clinical staging of the tumor and ruling out metastatic disease.
  • Locally advanced disease as defined per AJCC/UICC 8th edition37: stage IIA, IIB, III, IVA (T1-4a N2-3).
  • Eligibility for standard-of-care perioperative systemic therapy with FLOT+/-D.
  • Life expectancy greater than 3 months.
  • ECOG performance status < 2.

Exclusion criteria

  • Prior esophageal or gastric malignancy.
  • History of allergic reactions to simvastatin or atorvastatin or similar chemical or biological compounds.
  • Ongoing cholesterol-lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), in which case the patient is offered enrollment in the observational arm.
  • Hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range).
  • Predisposing factors for rhabdomyolysis: hypothyroidism, reduced renal function, muscle disease, or excessive alcohol consumption AND creatine kinase up to less than five times the upper limit (measured in the presence of predisposing factors).
  • Concurrent medication with potent CYP3A4-inhibitors, e.g. ketokonazole, erythromycin, gemfibrozil, cyclosporine, or danazol.
  • Pre-existing medical conditions precluding treatment, including any contraindication systemic chemotherapy or major surgery.
  • Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, discussed before registration in the trial.
  • Pregnant and breastfeeding women.
  • Unwillingness to undergo per-protocol investigations or treatments.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Canada · 1 center
  • McGill University Health Center — Montreal

Identifiers

NCT: NCT07625930 · THOR-ESO-2026-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗